These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7865333)

  • 1. Libraries of human rhinovirus-based HIV vaccines generated using random systematic mutagenesis.
    Resnick DA; Smith AD; Zhang A; Geisler SC; Arnold E; Arnold GF
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S47-52. PubMed ID: 7865333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A disulfide-bound HIV-1 V3 loop sequence on the surface of human rhinovirus 14 induces neutralizing responses against HIV-1.
    Zhang A; Geisler SC; Smith AD; Resnick DA; Li ML; Wang CY; Looney DJ; Wong-Staal F; Arnold E; Arnold GF
    Biol Chem; 1999 Mar; 380(3):365-74. PubMed ID: 10223339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of random systematic mutagenesis to generate viable human rhinovirus 14 chimeras displaying human immunodeficiency virus type 1 V3 loop sequences.
    Smith AD; Resnick DA; Zhang A; Geisler SC; Arnold E; Arnold GF
    J Virol; 1994 Jan; 68(1):575-9. PubMed ID: 8254775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1.
    Smith AD; Geisler SC; Chen AA; Resnick DA; Roy BM; Lewi PJ; Arnold E; Arnold GF
    J Virol; 1998 Jan; 72(1):651-9. PubMed ID: 9420270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeras from a human rhinovirus 14-human immunodeficiency virus type 1 (HIV-1) V3 loop seroprevalence library induce neutralizing responses against HIV-1.
    Resnick DA; Smith AD; Gesiler SC; Zhang A; Arnold E; Arnold GF
    J Virol; 1995 Apr; 69(4):2406-11. PubMed ID: 7884887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein engineering to create biologically active peptides: recombinant human rhinoviruses that display peptide sequences.
    Smith AD; Arnold E; Arnold GF
    Behring Inst Mitt; 1997 Feb; (98):229-39. PubMed ID: 9382744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
    J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric rhinoviruses as tools for vaccine development and characterization of protein epitopes.
    Arnold GF; Resnick DA; Smith AD; Geisler SC; Holmes AK; Arnold E
    Intervirology; 1996; 39(1-2):72-8. PubMed ID: 8957672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different immune response of mice immunized with conjugates containing multiple copies of either consensus or mixotope versions of the V3 loop peptide from human immunodeficiency virus type 1.
    Cruz LJ; Iglesias E; Aguilar JC; Cabrales A; Reyes O; Andreu D
    Bioconjug Chem; 2004; 15(5):1110-7. PubMed ID: 15366967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigenicity and predefined specificities of the multi-epitope vaccine in candidate consisting of neutralizing epitope and mutated epitopes suggested a new way against HIV-1 mutation.
    Tian H; Xiao Y; Qin L; Chen YH
    Immunobiology; 2001 Dec; 204(4):434-41. PubMed ID: 11776398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
    Gómez CE; Abaitua F; Rodríguez D; Esteban M
    Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses.
    Hewer R; Meyer D
    Vaccine; 2005 Mar; 23(17-18):2164-7. PubMed ID: 15755588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variable epitope libraries: new vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response.
    Charles-Niño C; Pedroza-Roldan C; Viveros M; Gevorkian G; Manoutcharian K
    Vaccine; 2011 Jul; 29(32):5313-21. PubMed ID: 21600948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based design of a constrained peptide mimic of the HIV-1 V3 loop neutralization site.
    Ghiara JB; Ferguson DC; Satterthwait AC; Dyson HJ; Wilson IA
    J Mol Biol; 1997 Feb; 266(1):31-9. PubMed ID: 9054968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 peptide vaccine candidates: selecting constrained V3 peptides with highest affinity to antibody 447-52D.
    Mester B; Manor R; Mor A; Arshava B; Rosen O; Ding FX; Naider F; Anglister J
    Biochemistry; 2009 Aug; 48(33):7867-77. PubMed ID: 19552398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformational preferences of a chimeric peptide HIV-1 immunogen from the C4-V3 domains of gp120 envelope protein of HIV-1 CAN0A based on solution NMR: comparison to a related immunogenic peptide from HIV-1 RF.
    Vu HM; de Lorimier R; Moody MA; Haynes BF; Spicer LD
    Biochemistry; 1996 Apr; 35(16):5158-65. PubMed ID: 8611499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative studies on neutralisation of primary HIV-1 isolates by human sera and rabbit anti-V3 peptide sera.
    Lawoko AL; Johansson B; Hjalmarsson S; Christensson B; Ljungberg B; Al-Khalili L; Sjölund M; Pipkorn R; Fenyö EM; Blomberg J
    J Med Virol; 1999 Oct; 59(2):169-79. PubMed ID: 10459152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.